Taysha Gene Therapies Stock EBITDA
| TSHA Stock | USD 1.93 0.05 2.66% |
Taysha Gene Therapies fundamentals help investors to digest information that contributes to Taysha Gene's financial success or failures. It also enables traders to predict the movement of Taysha Stock. The fundamental analysis module provides a way to measure Taysha Gene's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Taysha Gene stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | -94.7 M | -99.4 M |
Taysha | EBITDA |
Taysha Gene Therapies Company EBITDA Analysis
Taysha Gene's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Taysha Gene EBITDA | (105.2 M) |
Most of Taysha Gene's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Taysha Gene Therapies is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Taysha EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for Taysha Gene is extremely important. It helps to project a fair market value of Taysha Stock properly, considering its historical fundamentals such as EBITDA. Since Taysha Gene's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Taysha Gene's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Taysha Gene's interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
Taysha Ebitda
Ebitda |
|
According to the company disclosure, Taysha Gene Therapies reported earnings before interest,tax, depreciation and amortization of (105.2 Million). This is 111.99% lower than that of the Biotechnology sector and 205.03% lower than that of the Health Care industry. The ebitda for all United States stocks is 102.7% higher than that of the company.
Taysha EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Taysha Gene's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Taysha Gene could also be used in its relative valuation, which is a method of valuing Taysha Gene by comparing valuation metrics of similar companies.Taysha Gene is currently under evaluation in ebitda category among its peers.
Taysha Gene Current Valuation Drivers
We derive many important indicators used in calculating different scores of Taysha Gene from analyzing Taysha Gene's financial statements. These drivers represent accounts that assess Taysha Gene's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Taysha Gene's important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 468.8M | 438.6M | 99.3M | 205.5M | 236.4M | 462.5M | |
| Enterprise Value | 217.6M | 352.6M | 71.4M | 122.7M | 141.1M | 134.1M |
Taysha Gene Institutional Holders
Institutional Holdings refers to the ownership stake in Taysha Gene that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Taysha Gene's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Taysha Gene's value.| Shares | Tybourne Capital Management (hk) Ltd | 2024-09-30 | 3.7 M | Geode Capital Management, Llc | 2024-09-30 | 3.6 M | State Street Corp | 2024-09-30 | 3.5 M | Polar Capital Holdings Plc | 2024-09-30 | 3 M | Jpmorgan Chase & Co | 2024-09-30 | 3 M | Citadel Advisors Llc | 2024-09-30 | 2.9 M | Deutsche Bank Ag | 2024-09-30 | 2.6 M | Ghost Tree Capital, Llc | 2024-09-30 | 2.1 M | Longwood Capital Partners Llc | 2024-09-30 | 2.1 M | Fmr Inc | 2024-09-30 | 18.7 M | Venbio Select Advisor Llc | 2024-09-30 | 18.6 M |
Taysha Fundamentals
| Return On Equity | -1.15 | ||||
| Return On Asset | -0.27 | ||||
| Profit Margin | (2.30) % | ||||
| Operating Margin | (11.78) % | ||||
| Current Valuation | 290.14 M | ||||
| Shares Outstanding | 204.94 M | ||||
| Shares Owned By Insiders | 17.53 % | ||||
| Shares Owned By Institutions | 77.16 % | ||||
| Number Of Shares Shorted | 21.88 M | ||||
| Price To Book | 4.34 X | ||||
| Price To Sales | 39.89 X | ||||
| Revenue | 15.45 M | ||||
| Gross Profit | 2.5 M | ||||
| EBITDA | (105.2 M) | ||||
| Net Income | (111.57 M) | ||||
| Cash And Equivalents | 66.24 M | ||||
| Cash Per Share | 1.61 X | ||||
| Total Debt | 61.11 M | ||||
| Debt To Equity | 1.93 % | ||||
| Current Ratio | 1.79 X | ||||
| Book Value Per Share | 0.33 X | ||||
| Cash Flow From Operations | (73.02 M) | ||||
| Short Ratio | 3.66 X | ||||
| Earnings Per Share | 0.63 X | ||||
| Target Price | 6.59 | ||||
| Number Of Employees | 52 | ||||
| Beta | 0.41 | ||||
| Market Capitalization | 395.54 M | ||||
| Total Asset | 172.73 M | ||||
| Retained Earnings | (513.01 M) | ||||
| Working Capital | 113.11 M | ||||
| Net Asset | 172.73 M |
About Taysha Gene Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Taysha Gene Therapies's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Taysha Gene using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Taysha Gene Therapies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin |
Check out Taysha Gene Piotroski F Score and Taysha Gene Altman Z Score analysis. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Taysha Gene. If investors know Taysha will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Taysha Gene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.63 | Revenue Per Share | Quarterly Revenue Growth (0.62) | Return On Assets | Return On Equity |
The market value of Taysha Gene Therapies is measured differently than its book value, which is the value of Taysha that is recorded on the company's balance sheet. Investors also form their own opinion of Taysha Gene's value that differs from its market value or its book value, called intrinsic value, which is Taysha Gene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Taysha Gene's market value can be influenced by many factors that don't directly affect Taysha Gene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Taysha Gene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Taysha Gene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Taysha Gene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.